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Thyroid hormone (TH) is critical for cardiac development and heart
function. In heart disease, TH metabolism is abnormal, and many
biochemical and functional alterations mirror hypothyroidism. Al-
though TH therapy has been advocated for treating heart disease,
a clear benefit of TH has yet to be established, possibly because of
peripheral actions of TH. To assess the potential efficacy of TH in
treating heart disease, type 2 deiodinase (D2), which converts the
prohormone thyroxine to active triiodothyronine (T3), was ex-
pressed transiently in mouse hearts by using the tetracycline
transactivator system. Increased cardiac D2 activity led to elevated
cardiac T3 levels and to enhanced myocardial contractility, accom-
panied by increased Ca2 transients and sarcoplasmic reticulum
(SR) Ca2 uptake. These phenotypic changes were associated with
up-regulation of sarco(endo)plasmic reticulum calcium ATPase
(SERCA) 2a expression as well as decreased NaCa2 exchanger,
-myosin heavy chain, and sarcolipin (SLN) expression. In pressure
overload, targeted increases in D2 activity could not block hyper-
trophy but could completely prevent impaired contractility and SR
Ca2 cycling as well as altered expression patterns of SERCA2a,
SLN, and other markers of pathological hypertrophy. Our results
establish that elevated D2 activity in the heart increases T3 levels
and enhances cardiac contractile function while preventing dete-
rioration of cardiac function and altered gene expression after
pressure overload.
calcium  cardiac hypertrophy  sarcoplasmic reticulum  deiodinase 
transgenic mice
Thyroid hormone (TH) is essential for normal development invertebrates (1), with TH levels rising postnatally and peaking in
the third week of life (2). This surge is critical for fetal-to-adult
switch in the cardiac gene program and is responsible for changes
in Ca2 homeostasis, myosin isozyme content [-myosin heavy
chain (MHC)-to--MHC switch], and action potential profile (3, 4).
Intriguingly, the genetic and functional changes associated with
heart failure, such as reduced Ca2 transients and -MHC-to--
MHC shifts, which recapitulate the fetal gene program, are also
observed in hypothyroidism (5, 6). In addition, TH metabolism and
signaling are abnormal in heart failure (5, 7, 8). For example,
circulating and cardiac triiodothyronine (T3) levels (i.e., active TH)
are reduced in advanced heart disease, after acute myocardial
infarction, and in patients with cardiopulmonary bypass. These T3
changes occur in association with decreased peripheral conversion
of thyroxine (T4) into T3 (5, 8) and elevated cardiac deiodinase type
3 (D3) activity (9). TH receptor expression is also altered in
pathological hypertrophy (10), and myocardial contractility is im-
paired in mice lacking TH receptors (11). Not surprisingly, TH and
its analogue 3,5-diiodothyropropionic acid (DITPA) have been
advocated for treating heart failure (12, 13) and for reversing
cardiac dysfunction in patients with hypothyroidism (5), although
TH use has been limited by cardiotoxic effects of TH (14, 15).
Because of similarities between hypothyroidism and heart dis-
ease, we hypothesized that cardiac-specific enhancement of TH
signaling would prevent the genetic and functional defects in heart
failure. Type 2 deiodinase (D2) is a conserved 5 deiodinase enzyme
that is expressed in human myocardium, where it converts prohor-
mone T4 into active T3 (16, 17). We created transgenic mice that
conditionally overexpress D2 in the heart. D2 overexpression for 2
weeks caused enhanced contractile function in association with
changes in the expression of several calcium handling proteins.
After aortic banding (AB), D2 transgenic mice were resistant to
pressure overload-induced impairment of calcium cycling and
contractility, suggesting that cardiac-specific TH therapy may be
useful in treating heart disease patients.
Results
Effects of D2 Expression on Cardiac Function and Ca2 Cycling.
Doxycycline (DOX) withdrawal for 2 weeks did not affect heart
weight-to-body weight ratio or myocardial histology (Fig. 1C and
Table 1). Images of frozen heart sections revealed bright but patchy
fluorescence in DOX-withdrawn Bin-Off mouse hearts (mouse
lines are explained in detail in Methods), consistent with the
properties of the -myosin promoter used to drive tetracycline
transactivator (tTA) expression (18), whereas minimal fluorescence
was seen, as expected, in Con-Off hearts (Fig. 1C). Cardiac D2
expression (Fig. 1D), D2 activity (Fig. 1E), and T3 levels (Fig. 1F)
were elevated (P  0.05) in Bin-Off compared with Con-Off mice,
with no differences in D2 activity of liver, lung, and brain tissues
(Fig. 1E) or in cardiac T4 (Fig. 1G), serum T3 (Fig. 1H), or serum
T4 levels (Fig. 1I), confirming the cardiac-specific targeting of D2
activity.
Two weeks after DOX withdrawal, Bin-Off hearts had marked
elevations in cardiac contractility as assessed echocardiographically
or hemodynamically compared with Con-Off hearts (Table 1 and
Fig. 2 A and B), consistent with acute effects of exogenous TH (5,
19). No differences in cardiac function were observed between
Con-Off, Con-On, and Bin-On mice (data not shown). Enhanced
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cardiac function in Bin-Off mice resembles that observed in acutely
TH-treated mice (19). To examine whether these functional dif-
ferences were related to TH, mice were made hypothyroid by
feeding 5-propyl-2-thiouracil (PTU) (see Methods) before DOX
withdrawal. As expected (19), serum T4 levels (16 of control
values) and myocardial contractility (Table 1) were reduced (P 
0.05) in hypothyroid mice. However, DOX withdrawal, despite
significant elevations in D2 mRNA levels (data not shown), was not
accompanied in hypothyroid Bin-Off mice by increased myocardial
contractility (Table 1), suggesting that the cardiac phenotype in
euthyroid Bin-Off mice is TH-dependent.
The cellular mechanisms for elevated contractility in Bin-Off
mice was investigated by measuring cell shortening and Ca2
transients in myocytes isolated 2 weeks after DOX withdrawal. The
percentage of cell shortening (CS), dLdtmax (rate of contrac-
tion), dLdtmax (rate of relaxation), and Ca2 transient ampli-
tudes (Fig. 2 C–F and Table 2) were increased (P  0.01) along with
enhanced (P  0.05) Ca2 transient decay kinetics (T50) (Fig. 2F)
in Bin-Off mice compared with Con-Off mice.
The cellular results indicate greater sarcoplasmic reticulum (SR)
Ca2 ATPase activity in Bin-Off mice. In agreement with this
conclusion, the thapsigargin-sensitive Ca2 uptake measurements
in isolated SR vesicles showed increased (P  0.005) maximal SR
Ca2 uptake rates (Vmax) and no differences in the [Ca2] required
for half-maximal activity (i.e., EC50) in Bin-Off mice compared with
Con-Off mice (Fig. 2G). Enhanced SR Ca2 uptake in Bin-Off mice
suggests increased SR Ca2 loads. Indeed, after caffeine applica-
tion, the peak INCX (where NCX is NaCa2 exchanger) and the
time integral of INCX, which reflects the total amount of Ca2
present in the SR (20), were elevated in Bin-Off myocyte (Fig. 3 A
and B). The enhanced Ca2 transients and Ca2 load in Bin-Off
mice occurred without differences in action potential profile (Fig.
3C), L-type Ca2 current (Fig. 3D), or K currents (Fig. 3E), each
of which can affect independently Ca2 transients and myocyte
contractility (20).
Effects of D2 on Gene Expression. Because TH exerts many of its
functional effects through transcriptional regulation (5) and be-
cause Ca2 transients and myocyte contractility were elevated in
Bin-Off mice, we measured mRNA levels of selected TH-regulated
cardiac genes. Somewhat surprisingly, no differences were observed
for sarco(endo)plasmic reticulum calcium ATPase (SERCA)2a
(Fig. 4A) or for NCX, phospholamban (PLN), KV1.5, and KV4.23
mRNA levels (data not shown) between Bin-Off and Con-Off mice,
whereas large reductions (P  0.05) in -MHC and sarcolipin
(SLN) mRNA were detected 2 weeks (Fig. 4A) after DOX with-
drawal. Because SR Ca2 uptake rates and content were increased
in Bin-Off mice and because TH can have nontranscriptional
effects (5, 21, 22), we examined protein levels of NCX, SERCA2a,
and PLN. Although PLN levels were not different, SERCA2a
protein was elevated (P  0.05), whereas NCX protein was reduced
(P  0.005), in Bin-Off mice compared with Con-Off mice (Fig. 4
D–F), consistent with previous studies in mice acutely treated with
TH (23). The reduced NCX protein explains the increased (P 
Fig. 1. Cardiac-targeted expression of D2. (A) Results of genotyping by PCR
showing a 724-bp product plus a 585-bp product for mice heterozygous for the
D2 transgene (tD2) and a 585-bp product for WT mice (see Methods). (B)
Schematic representation of the tetracycline-regulated mammalian gene ex-
pression system. tTA and EGFP refer to the tetracycline-controlled transacti-
vator fusion protein and the reporter gene EGFP, respectively. (C) Represen-
tative gross morphology of whole hearts and confocal microscopy images
showing fluorescent signal in Con-Off (Left) and Bin-Off (Right) mice. (D) D2
mRNA levels in Bin-Off mice relative to Con-Off mice. (E) D2 activity in heart,
liver, lung, and brain of Bin-Off and Con-Off mice (n  4). (F–I) Cardiac T3 (F)
and T4 (G) levels (n  10) as well as circulating T3 (H) and T4 (I) levels (n  6)
in Bin-Off and Con-Off mice (#, P  0.05 in Bin-Off mice compared with all
groups; *, P  0.005 in Bin-Off vs. Con-Off mice).














HR, bpm 511  8.9 513  22.8 527  6 524  8 380  19* 347  5.8*
AWT, mm 0.66  0.02 0.69  0.01 0.65  0.01 0.66  0.01 0.56  0.01 0.58  0.01
LVEDD, mm 4.19  0.09 4.27  0.07 4.26  0.04 4.21  0.03 3.89  0.08 3.99  0.03
LVESD, mm 2.21  0.05 2.02  0.08 2.19  0.07 2.01  0.04 2.54  0.08* 2.62  0.04*
FS, % 48.1  1.2 55.8  1.3† 48.6  1.1 56.1  1.3† 35.9  1.1* 34.3  1*
VCFc, circs 9.05  0.2 11.7  0.4† 9.73  0.23 11.81  0.23† 4.4  0.21* 4.5  0.14*
PAVc, cms 95.1  2 112.6  3.2† 93.3  2.5 114.7  2.1† 73.4  4* 72  2.2*
AVA, ms2 57.3  1.9 78.8  2.2† 49.2  2.2 73.5  1.9† 33.2  1.8* 30.4  2.2*
HWBW, mgg 5.2  0.2 5.5  0.3 4.79  0.2 5.4  0.3
HR, heart rate; bpm, heart beats per min; AWT, anterior wall thickness; LVEDD, left ventricle end diastolic dimension; LVESD, left ventricle end systolic
dimension; FS, fractional shortening; VCFc, velocity of circumferential fiber shortening (circ, circumferences) corrected for HR; PAVc, peak aortic outflow velocity
corrected for HR; AVA, aortic velocity acceleration (PAVcacceleration time); PTU, 5-propyl-2-thiouracil; HWBW, heart weightbody weight. *, P  0.01
compared with corresponding group not treated with PTU; †, P  0.01 compared with all groups.
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0.05) time constants for the decay of INCX (i.e., NCX) after caffeine
application (Fig. 3 A and B).
Although enhanced Ca2 handling and contractility in the Bin-
Off mice is expected to result from altered SERCA2a and NCX
protein expression, reductions in SLN mRNA are intriguing, be-
cause SLN is a PLN homologue (24–26); this reduction also implies
that SLN is regulated by TH. Indeed, SLN mRNA levels were
reduced by 40% (P  0.05) in mice made hyperthyroid by
treatment with exogenous TH (Fig. 4B) and were elevated in
hypothyroid mice that were fed PTU (Table 1 and Fig. 4C).
Prolonged TH treatment has been shown to impair heart func-
tion, possibly because of (peripheral) extracardiac effects (14, 27,
28). As shown in Tables 1 and 2 (see also Table 3, which is published
as supporting information on the PNAS web site), not only was
deterioration of heart function not observed, but cardiac contrac-
tility and Ca2 transients remained elevated in Bin-Off mice 9
weeks after being withdrawn from DOX compared with Con-Off
mice. Moreover, the differences in mRNA and protein expression
and SR Ca2 uptake (data not shown) observed between Bin-Off
and Con-Off mice after 2 weeks of DOX withdrawal were identical
to those observed after 9 weeks of DOX removal. Therefore, the
positive inotropic effects of D2 overexpression persist for prolonged
periods.
Prevention of Heart Failure by Cardiac Expression of D2. Previous
studies have suggested that impaired TH signaling and altered TH
metabolism occur in heart disease and might contribute to disease
pathogenesis (8–10). On the other hand, elevated TH induces heart
disease, possibly as a result of peripheral actions (14, 27, 28). To
assess whether cardiac-restricted D2 overexpression is beneficial in
heart disease, 8-week-old mice were DOX withdrawn and subjected
to AB for 9 weeks. Echocardiographic and hemodynamic assess-
ment of myocardial performance showed deterioration of myocar-
dial contractile function accompanied by atrial and ventricular
dilation of banded Con-Off (Con-Ban) mice compared with sham-
operated Con-Off (Con-Sham) mice, whereas all of the functional
alterations seen in Con-Ban mice were prevented in Bin-Off
banded (Bin-Ban) mice (Table 2). We found that Con-Sham mice,
after 9 weeks of DOX withdrawal, were indistinguishable both
functionally (compare Tables 1 and 2) and biochemically (see
below) from Con-Off mice 2 weeks or 9 weeks after DOX with-
drawal. Therefore, Con-Sham data will not be presented. The
differences between Con-Sham and Con-Ban or Bin-Ban mice can
also be readily assessed by comparing the results in Figs. 1–4 with
those in Fig. 5.
Despite protecting heart function, D2 overexpression had no
effect on myocardial hypertrophy (Fig. 5A), establishing that D2
overexpression in the heart allows cardiac hypertrophy to be
dissociated from contractile dysfunction (Fig. 5 B–F). Consistent
with this, mouse hearts overexpressing D2 were protected against
increased expression of pathological hypertrophy markers (KV4.3,
atrial natriuretic factor, and -MHC) in response to AB, as shown
Fig. 2. Enhancement in cardiac contractility in binary transgenic mice. (A and
B) Representative M-mode echocardiograms (A) and aortic velocity profiles (B)
in Con-Off and Bin-Off mice. LVEDD, left ventricle end-diastolic dimension;
LVESD, left ventricle end-systolic dimension. (C) Representative contractions
of cardiomyocytes isolated from Con-Off and Bin-Off mice. (D) Mean percent-
age of CS, rate of contraction (dLdtmax), and rate of relaxation (dLdtmax)
in field stimulated myocytes. (E) Representative traces of the ratio of Indo-1
fluorescence measured at 405 nm divided by 485 (F405/F485) in Con-Off and
Bin-Off mice. (F) Amplitude (A405/485) and time to 50% decay (T50) of Indo-1
fluorescence ratio (F405F485) to assess Ca2 transients. (G) Maximal rate of SR
Ca2 uptake (Vmax) in cardiac SR vesicles isolated from Bin-Off relative to
Con-Off mice (n  15; #, P  0.05).
Table 2. Cardiac morphology and function in mice after pressure








HR, bpm 527  6 536  14 526  11
AWT, mm 0.65  0.01 0.85  0.01 0.87  0.02
LVEDD, mm 4.26  0.09 4.94  0.09* 4.52  0.06
LVESD, mm 2.19  0.07 3.62  0.12* 2.46  0.08
FS, % 49.2  1.1 26.6  2.1* 46.6  1.3
VCFc, circs 9.74  0.23 5.25  0.42* 9.62  0.26
PAVc, cms 93.3  2.5 79.7  2.4* 107.2  3.4†
AVA, ms2 51.6  2.1 40.5  1.6* 64.9  2.4†
dpdtmax, mmHgs 7925  536 5359  668* 10393  517†
dpdtmax, mmHgs 7163  347 5540  699* 10307  373
HWBW, mgg 4.79  0.17 8.79  0.78† 7.51  0.73†
dpdtmax, maximum positive time derivative of the left ventricular pres-
sure; dpdtmax, maximum negative time derivative of the left ventricular
pressure. Other abbreviations are as in Table 1. *, P  0.01 compared with all
groups; †, P  0.01 compared with Con-Sham.
Fig. 3. Effects of D2 overexpression on myocyte properties. (A) Bar graphs
summarizing studies measuring NCX current (INCX) in myocytes after caffeine
application: peak INCX (INCX
peak), time integral of INCX (INCX), and INCX decay times
(NCX). (B) Typical INCX traces elicited by application of 20 mmolliter caffeine
to myocytes isolated from Con-Off and Bin-Off hearts. (C–E) Typical action
potentials (C), L-type Ca2current families (D), and transient outward K
current families (E) recorded in myocytes isolated from Con-Off and Bin-Off
mice (n  15; #, P  0.05; *, P  0.005 in Bin-Off vs. Con-Off mice).







in Fig. 5G (6). At the cellular level, it is clear from Fig. 2, that
myocyte contractility, Ca2 transients, and SR Ca2 uptake rates
are reduced in Con-Ban compared with Con-Sham myocytes,
whereas Bin-Ban mice were again completely protected against
these changes. The cellular changes observed in Con-Ban mice were
associated with corresponding reductions (P  0.05) in SERCA2a,
without alterations in PLN and NCX protein levels (Fig. 5H vs. Fig.
4 D–F) compared with Con-Off mice. Remarkably, the changes in
SLN (Fig. 5G) and SERCA2a (Fig. 5H) induced by AB were
completely prevented in Bin-Ban mice, possibly underlying the
increases in Ca2 transients as well as the increased maximal rate
of SR Ca2 uptake observed in those mice. Taken together, these
results establish that D2 overexpression can rescue both functional
and pathological genetic remodeling induced by AB.
It could be argued that the preservation of cardiac function
occurs in response to D2 overexpression after AB because heart
function is elevated by D2 overexpression in the absence of pressure
overload. However, careful comparisons of the in vivo functional
differences reveal that the relative functional impairment in Bin-
Ban mice compared with Bin-Off mice (9 weeks post-DOX) is
approximately four-fold less than that observed in Con-Ban com-
pared with Con-Off mice (compare Tables 1 and 2). Similarly, the
reduction in CS was much less in Bin-Ban vs. Bin-Off mice (at 9
weeks post-DOX) than that observed between Con-Ban and Con-
Off mice. For example, the percentage of CS is reduced by 43  4%
in the Con-Ban mice compared with Con-Off (or Con-Sham) mice
but is reduced by only 10.3  2.2% in Bin-Ban mice compared with
Bin-Off mice (9 weeks). Similar differences in the relative changes
between Con-Ban and Con-Off mice vs. Bin-Ban and Bin-Off mice
apply to the amplitude of calcium transient and the dLdtmax
(Table 3, Fig. 5 C–F, and data not shown). These observations
demonstrate that the benefit of D2 overexpression after pressure
overload does not simply originate from enhanced contractile
function seen with D2 overexpression in nonbanded hearts.
Discussion
D2 converts the prohormone TH, T4, to active T3 (16, 17) and is
the primary source of T3 in many tissues of the body, such as brain
and human heart. Because altered TH signaling or metabolism is
postulated to occur in heart disease (5, 7, 8) and because TH has
been advocated as cardiac disease treatment (12), we created mice
conditionally expressing D2 in the heart (18). Scrupulous feeding of
DOX beginning before conception allows the separation of acute
actions from chronic actions of TH while also avoiding develop-
mental effects of TH (18). This is critical because developmental
maturation of the heart is regulated by TH(1) and the -MHC
promoter used to drive D2 expression is activated during embry-
ogenesis (29).
Consistent with the actions of D2, transient D2 overexpression
for 2 weeks led to elevations in cardiac T3 levels without affecting
serum T4 and T3 levels, which was associated with increased
myocardial contractility and Ca2 transients, as reported with acute
exogenous TH treatment (5, 19). These functional changes ap-
peared to be related to D2-mediated enhancements of T3, because
DOX withdrawal of hypothyroid D2 mice did not affect contrac-
tility. A recent study suggested that tTA overexpression alone
depresses contractility in vivo and elevates it in vitro (30). This was
not observed in our DOX-withdrawn tTA-positive mice, consistent
with previous studies (31).
Many effects of elevated TH levels occur by means of nuclear TH
receptors (i.e., TH receptor  and TH receptor ), leading to
transcriptional regulation of many cardiac genes, particularly those
involved in Ca2 cycling (5). Consistent with elevated TH in the
hearts of mice overexpressing D2, we observed increases in Ca2
transients, SR Ca2 stores, and the maximal rate of SR Ca2 uptake
(Vmax) without alterations in the Ca2 dependence of SR Ca2
uptake (i.e., EC50). These changes were associated with increased
Fig. 4. Effects of D2 overexpression and TH on mRNA and protein levels. (A)
Fractional changes in myocardial mRNA levels of SERCA2a, SLN, and -MHC.
GAPDH levels were used as a loading control (n  5). (B) Changes in myocardial
mRNA levels of SERCA2a, SLN, and -MHC in ICR WT type mice (n  4) after i.p.
injection with L-thyroxine. (C) SLN mRNA expression relative to GAPDH in
hearts from ICR WT mice and Bin-Off and Con-Off mice treated with a
PTU-containing diet. (D–F) Western blots and relative quantifications of
SERCA2a (D), PLN (E), and NCX (F) in Con-Off and Bin-Off mice. Blots were
probed with calsequestrin antibody to check for equality in protein loading
(n  3 for each genotype; #, P  0.05; *, P  0.005 in Con-Off vs. Bin-Off mice
and in euthyroid vs. hypothyroidhyperthyroid mice).
Fig. 5. D2 expression prevents the development of the molecular and func-
tional changes associated with heart failure. (A and B) Representative gross
morphology of whole hearts from Con-Ban and Bin-Ban mice. (C and D) Repre-
sentative recordings of CS (C) and Ca2 transients (Indo-1 fluorescence ratio) (D)
in field stimulated myocytes isolated from Con-Ban and Bin-Ban mice. (E) Sum-
marized data for percentage of CS and maximal rate of contraction (dLdtmax)
and relaxation (dLdtmax). (F) Summarized results of Indo-1 fluorescence ratio
amplitudes (A405/485) measured in myocytes to assess Ca2 transient amplitudes as
well as maximal rate of ventricular SR Ca2 uptake (Vmax) in isolated SR vesicles.
(G and H) Ventricular mRNA levels of SLN, -MHC, atrial natriuretic factor, and
KV4.3 (G) and ventricular protein levels of SERCA2a, PLN, and NCX (H) in Con-Ban
and Bin-Ban mice (n  15; #, P  0.05 in Con-Ban vs. Bin-Ban mice).
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expression of SERCA2a but not PLN, suggesting that SERCA2a
elevations are responsible for the enhanced Ca2 cycling and
contractility in D2-overexpressing mice. However, D2 overexpres-
sion also reduced the levels of SLN, which can impair cardiac
contractility and depress Ca2 cycling (26, 32) in mouse myocar-
dium as a result of either direct SERCA inhibition or synergistic
interaction with PLN to form highly stable ternary SLNPLN
SERCA2a complexes (24, 25). Depressed SLN levels in D2-
overexpressing hearts appeared to be TH-dependent, because SLN
expression was decreased in hyperthyroid hearts and increased in
hypothyroid hearts. Thus, although SLN expression in mouse
ventricles is low compared with atria (33) (M.G.T., unpublished
data), our results support the possibility that SLN changes contrib-
ute to changes in Ca2 cycling and contractility observed in the
D2-overexpressing mice. Future studies are clearly warranted to
unravel the potential role for SLN in Ca2 homeostasis.
D2 overexpression also reduced NCX protein expression without
changing its mRNA levels. This uncoupling between mRNA and
protein could reflect posttranscriptional actions of elevated T3
levels in the D2 mice, as seen for other genes after TH treatment
(22). Regardless, reduced NCX protein correlated with slower
decay rates of INCX currents after SR Ca2 release with caffeine (34)
in D2-overexpressing mice. The functional consequence of reduced
NCX activityexpression is difficult to predict because of complex
interactions among NCX, SR, Ca2 transport, membrane potential,
transmembrane gradients of Ca2 and Na, and other cellular
factors (35). Nevertheless, the conventional view has been that
elevated NCX reduces contractility and Ca2 cycling by depleting
the SR of Ca2 by means of the promotion of Ca2 extrusion from
the cytosol (36), which contributes to the negative force–frequency
relationship and diastolicsystolic dysfunction (36, 37). Collectively,
these observations suggest that reduced NCX levels in D2-
overexpressing mice contribute to elevations of Ca2 transients
and contractility. Further studies are required to validate this
conclusion.
D2 expression and elevated T3 levels in the heart were further
associated with decreased expression of slow -MHC levels and
reduced -MHC-MHC ratios, a pattern already observed in
response to TH treatment in mouse (38). Because small increases
in -MHC-MHC ratios correlate with impaired cardiac function
(39, 40) and because small elevations of -MHC disproportionately
slow contractile speed (40), it is conceivable that reduced -MHC
expression contributes to the increased myocardial contractility
seen in our D2-overexpressing mice.
It is interesting to note that the molecular changes observed in
our mice overexpressing D2 also occur in the postnatal period as a
result of an endogenous TH surge (2, 4, 23). In contrast, the
complex changes observed in heart disease recapitulate the fetal
phenotype and mimic hypothyroidism (5, 8). Additionally, abnor-
mal TH signalingmetabolism is reported in both heart disease and
after cardiopulmonary bypass surgery (5, 7). Thus, TH therapy has
been advocated for treating cardiac disease (12, 13), although clear
benefit has been difficult to demonstrate, particularly with chronic
use, possibly because of adverse extracardiac effects of TH (5, 27).
The response of our D2-overexpressing mice to AB supports the
conclusion that cardiac-restricted T3 production by D2 protects
against deterioration of heart function induced by pressure over-
load. This preservation of heart function is undoubtedly complex
but is likely related to Ca2 cycling. Indeed, reduced expression of
SERCA2a, along with impaired Ca2 transients and SR Ca2
uptake rates induced by pressure overload, were completely ame-
liorated in D2 transgenic mice, consistent with the beneficial effects
of restored SERCA2aPLN ratios in heart disease (41). Some of
the protection could also be related to SLN, consistent with recent
studies showing elevated SLN in the diseased heart (42).
Because T3 modulates the expression of many genes, it is
conceivable that other genetic changes help to optimize the bene-
ficial actions of TH on heart function. For example, down-
regulation of KV4.3-encoding Ito and increased -MHC-MHC
ratio, both of which are prevented in D2-overexpressing mice
subjected to pressure overload, have been suggested to contribute
to depressed cardiac function in heart disease (39, 40, 43). On the
other hand, although defective Ca2 handling in heart disease has
also been linked to elevated NCX expressionactivity leading to SR
Ca2 depletion and negative force–frequency relationships (35), no
NCX expression changes were observed in mice after pressure
overload, as reported previously (36, 37).
As already mentioned, the benefit of D2 overexpression was
not simply related to the enhanced baseline contractibility
(compare Tables 1 and 2). Rather, protection against pressure
overload in mice with increased D2 expression could be related
to the reversal of a local cardiac hypothyroidism or correction of
the altered TH signaling that is postulated to occur in diseased
hearts (5, 7, 9). Consistent with a local hypothyroidism, we find
that in response to pressure overload for 9 weeks there is a nearly
5-fold increase in the expression of the type 3 deiodinase (D3),
an enzyme that converts T4 and T3 into inactive metabolites,
such as reverse-T3 (rT3) (M.G.T., unpublished data). Because
D2 can use rT3 as substrate, increased expression of D2 is
expected to enhance TH signaling by countering the effects of
elevated D3. Alternatively, elevated TH in our D2 mice could
simply reverse the changes in gene expression and function
induced by the activation of various hypertrophic signaling
pathways involved in heart failure, either by directly regulating
genes by means of T3 response elements or by interactions with
other transcription factors regulating genes with altered expres-
sion in heart disease. For example, TH receptors interact with
MEF2a (myocyte enhancer factor 2A), a known transcriptional
modulator of pathological cardiac growth in myocytes (6, 44).
Regardless of the precise mechanism of protection, our results
establish that the functional rescue produced by cardiac-specific
increases in D2 activity occurs without prevention of increased
heart weight-to-body weight ratios. These observations are con-
sistent with the notion that controlled hypertrophy without
(excessive) changes in the expression of pathologic hypertrophic
markers, such as -myosin, Kv4.3, and atrial natriuretic factor, as
observed in response to exercise (6) and in our D2 mice, is
beneficial.
In conclusion, our results demonstrate that cardiac-targeted
increases in the D2 activity cause TH-dependent elevations of
myocardial contractility and Ca2 cycling in association with re-
ductions in the levels of SLN, NCX, -MHC and elevation in
SERCA2a levels. Our studies further establish that increased D2
activity can preserve heart function and normalize the expression
of several genes involved in pathological remodeling, suggesting
that cardiac-specific TH delivery may be an effective treatment in
heart disease. However, because our conclusions are based on a
rodent model of cardiac disease, it is difficult to predict whether the
same approach might be successful in humans. Furthermore, our
studies evaluated the effects of D2 overexpression in preventing the
development of disease but did not explore the impact that D2
might have at different time points during the course of the disease
or when cardiac disease is already established. Future studies are
clearly mandatory to validate the therapeutic implications of our
results.
Methods
Mouse Maintenance. Chimeric rat D2 (tgD2) (16) was subcloned in
a bidirectional vector [modified pBig (Clontech), with lacZ coding
sequence replaced by EGFP] to allow simultaneous expression of
D2 and EGFP under the control of the tTA. Two transgenic lines
were generated. The results below were obtained in the D2-I line,
with similar findings being observed in the second line. Transgenic
mice were genotyped by PCR to differentiate between the endog-
enous D2 (585 bp) and transgenic D2 (724 bp) (Fig. 1 A and B). For
most studies, homozygous D2 (tgD2/) males were crossed with







heterozygous (tTA/) females expressing the tTA under the
control of the -myosin promoter (kindly provided by Glen Fish-
man, New York University School of Medicine, New York), to
produce binary mice expressing tgD2 and tTA (tgD2/tTA/,
Bin) or littermate control mice positive for D2 only (tgD2/
tTA/, Con). The frequency of various genotypes followed the
expected Mendelian pattern. D2 activity was observed in Bin mice
but not Con mice (Fig. 1 D and E). Although controls used for the
results presented below were tgD2/tTA/, identical findings
were obtained in tgD2/tTA/ and WT tgD2/tTA/ mice.
Because TH affects prenatal and postnatal gene expression (1, 5),
mothers were administered 0.1% DOX along with 0.5% sucrose in
the drinking water for 2–4 weeks before conception until weaning.
Offspring were continued on oral DOX until 8–10 weeks of age, at
which time DOX was either maintained (Bin-On and Con-On) or
removed (Bin-Off and Con-Off). Mice (ICR strain) were made
hyperthyroid by daily i.p. injection of L-thyroxine (5 gg of body
weight) for 8 days and hypothyroid by administering a 0.15%
PTU-containing diet (Teklad Premier; Teklad, Madison, WI) for 5
weeks. All studies were performed in accordance with the stan-
dards of the Canadian Council on Animal Care.
SERCA Uptake Assay. SR Ca2 transport activity was determined as
described in ref. 24. The SERCA-specific inhibitor thapsigargin at
1 M was used to block Ca2 uptake and to estimate the contri-
bution of other Ca2 pumps to the measured 45Ca2 uptake.
Aortic Banding in Mice. Descending AB was performed in 8-week-
old mice, and the mice were assessed 9 weeks later. Adminis-
tration of DOX to mice was discontinued 1 week before banding
surgery.
Data Analysis. One-way ANOVA combined with the Student–
Newman–Keuls test for multiple comparisons between groups was
used to test for statistical significance (SPSS 11; SPSS, Chicago). For
the expression studies (mRNA and protein levels), Dunnett’s
multiple comparisons test was used. Values are shown as mean 
SEM.
The remaining methods can be found in Supporting Methods
and Table 4, which are published as supporting information on
the PNAS web site.
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